Intraobserver and interobserver evaluation in the radiological diagnosis of bisphosphonate-related fractures

Main Article Content

Guido Carabelli
Jorge Daniel Barla
Danilo Eric Taype
Carlos Federico Sancineto

Abstract

ObjetiveEvaluate the utility of radiography for diagnosing bisphosphonate-related atypical fractures. MethodsPatients with a subtrochanteric and diaphyseal femur fracture, admitted to the institution from 2006 to 2011, have been retrospectively reviewed. Exclusion criteria included neck, intertrochanteric and supracondylar femoral fractures, pathological fractures and paediatric patients. All clinical data of 167 patients were reviewed from case records of which 29 had a bisphosphonate-related atypical femoral fractures.Out of 169 fractures classified (including 2 bilateral patients), 109 were diaphyseal and 60 subtrochanteric.Seven MD orthopaedics divided in 3 groups reviewed all radiographs of the 169 fractures retrospectively, independently and twice. The three groups readers were different expertise levels (group 1: 3 residents in the third year; group 2: one fellowship in knee and the other one in shoulder; group 3: one expertise in hip prothesis and another in foot and ankle).The following information has been included in the readers’ data collection sheets: focal lateral cortical thickening, transverse orientation of fracture and medial spike.The three fracture characteristics were assessed as present or absent and were recorded as: YES for three criteria present,  DON´T KNOW  for two criteria present and NO for 0 criteria present. The intraobserver agreement was calculated with  kappa coefficients  while the interobserver agreement was calculated with the G-string program. The statistical analysis applied was YES for data with 3 criteria. ResultThe intraobserver agreement was kappa = 0.2 to 0.5. The Interobserver agreement was 54 % average.  ConclusionRadiographs alone are not reliable enough for distinguishing complete femoral fractures related to bisphosphonate.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
Carabelli, G., Barla, J. D., Taype, D. E., & Sancineto, C. F. (2015). Intraobserver and interobserver evaluation in the radiological diagnosis of bisphosphonate-related fractures. Revista De La Asociación Argentina De Ortopedia Y Traumatología, 80(4), 230-234. https://doi.org/10.15417/382
Section
Clinical Research
Author Biographies

Guido Carabelli, Hospital Italiano de Buenos Aires

Médico de planta del Sector de Trauma

Jorge Daniel Barla, Hospital Italiano de Buenos Aires

medico de planta sector trauma ortopedico

Danilo Eric Taype, hospital italiano de buenos aires

medico asociado a sector trauma ortopedico

Carlos Federico Sancineto, Hospital Italiano de Buenos Aires

Jefe de Servicio de Ortpedia y Traumatologia

References

1. Schilcher J, Aspenberg P. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop
2009;80:413-5.

2. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. Ten years’ experience with alendronate for
osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99.

3. Das De S, Setiobudi T, Shen L, Das De S. A rational approach to management of alendronate-related subtrochanteric fractures.
J Bone Joint Surg Br 2010;92:679-86.

4. Edwards BJ, Bunta AD, Lane J, Odvina C, Rao DS, Raisch DW, et al. Bisphosphonates and nonhealing femoral fractures:
analysis of the FDA Adverse Event Reporting System (FAERS) and International Safety Efforts. J Bone Joint Surg Am
2013;95:297-307.

5. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate
use. J Orthop Trauma 2008; 22:346-50.

6. Rosenberg ZS, La Rocca Vieira R, Chan SS, Babb J, Akyol Y, Rybak LD, et al. Bisphosphonate-related complete atypical
subtrochanteric femoral fractures: diagnostic utility of radiography. AJR 2011;197(4):954-60.

7. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: A potential complication
of alendronate therapy. J Clin Endocrinol Metab 2005;90(3):1294-1301.

8. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on
risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:
1535-41.

9. Nieves JW, Bilezikian JP, Lane JM, Einhorn TA, Wang Y, Steinbuch M, et al. Fragility fractures of the hip and femur: incidence
and patient characteristics. Osteoporos Int 2010;21:399-408.

10. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their
potential influence on clinical efficacy. Osteoporos Int 2008;19:733-59

Most read articles by the same author(s)